Universe Pharmaceuticals Inc. - UPC Enterprise Value-to-Revenue Multiple

Public company logo of universe-pharmacy.com (UPC)

The growth foundation of Universe Pharmaceuticals (UPC) is based on years of trust in the quality of its herbal products. The EV/Sales ratio visualizes this trend, where -714.21 records a new level. Premium pricing in the phytotherapy niche supports margins, although consumables are price-constrained. Business stability relies on a safe liquidity buffer while maintaining government compliance in the PRC.

Universe Pharmaceuticals Inc. - UPC Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Universe Pharmaceuticals Inc. - analytical breakdowns and key metrics (UPC)

Initial company analysis:universe-pharmacy.com UPC
Product sample of Universe Pharmaceuticals INC

An investment audit of Universe Pharmaceuticals (UPC) requires verifying that market value aligns with actual sales volumes. This EV/Revenue multiple aggregates market capitalization and net debt, dividing them by annual turnover to identify asset overvaluation. Given the dependence of Universe Pharmaceuticals (UPC) on Chinese pharmacy retail and government compliance, this chart enables monitoring of business margins, confirming capital stability.